drugset / Trial / NCT05198596

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

NCT05198596

Phase 3 Completed 250 enrolled Medigen Vaccine Biologics Corp.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.

Timeline

Start
2022-07-30
Primary completion
2022-11-04
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD1222 Vaccine Intramuscular
Subject MVC-COV1901 Vaccine Intramuscular

Indications

No indication recorded.